Your browser doesn't support javascript.
loading
Nationwide Outcome after Pancreatoduodenectomy in Patients at very High Risk (ISGPS-D) for Postoperative Pancreatic Fistula.
Theijse, Rutger T; Stoop, Thomas F; Hendriks, Tessa E; Suurmeijer, J Annelie; Smits, F Jasmijn; Bonsing, Bert A; Lips, Daan J; Manusama, Eric; van der Harst, Erwin; Patijn, Gijs A; Wijsman, Jan H; Meerdink, Mark; den Dulk, Marcel; van Dam, Ronald; Stommel, Martijn W J; van Laarhoven, Kees; de Wilde, Roeland F; Festen, Sebastiaan; Draaisma, Werner A; Bosscha, Koop; van Eijck, Casper H J; Busch, Olivier R; Molenaar, I Quintus; Groot Koerkamp, Bas; van Santvoort, Hjalmar C; Besselink, Marc G.
  • Theijse RT; Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
  • Stoop TF; Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Hendriks TE; Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
  • Suurmeijer JA; Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Smits FJ; Division of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.
  • Bonsing BA; Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
  • Lips DJ; Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Manusama E; Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
  • van der Harst E; Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
  • Patijn GA; Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Wijsman JH; Department of Surgery, Regional Academic Cancer Center Utrecht, University Medical Center Utrecht and St. Antonius Hospital Nieuwegein, Utrecht University, the Netherlands.
  • Meerdink M; Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
  • den Dulk M; Department of Surgery, Medisch Spectrum Twente, Enschede, the Netherlands.
  • van Dam R; Department of Surgery, Medisch Centrum Leeuwarden, the Netherlands.
  • Stommel MWJ; Department of Surgery, Maasstad Hospital, Rotterdam, the Netherlands.
  • van Laarhoven K; Department of Surgery, Isala Clinics, Zwolle, the Netherlands.
  • de Wilde RF; Department of Surgery, Amphia Hospital, Breda, the Netherlands.
  • Festen S; Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands.
  • Draaisma WA; Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands.
  • Bosscha K; Department of General, Visceral and Transplant Surgery, University Hospital Aachen, Germany.
  • van Eijck CHJ; NUTRIM-School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, the Netherlands.
  • Busch OR; Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands.
  • Molenaar IQ; Department of General, Visceral and Transplant Surgery, University Hospital Aachen, Germany.
  • Groot Koerkamp B; Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.
  • van Santvoort HC; Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Besselink MG; Department of Surgery, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
Ann Surg ; 2023 Dec 11.
Article en En | MEDLINE | ID: mdl-38073575
ABSTRACT

OBJECTIVE:

To assess nationwide surgical outcome after pancreatoduodenectomy (PD) in patients at very high risk for postoperative pancreatic fistula (POPF), categorized as ISGPS-D. SUMMARY BACKGROUND DATA Morbidity and mortality after ISGPS-D PD is perceived so high that a recent randomized trial advocated prophylactic total pancreatectomy (TP) as alternative aiming to lower this risk. However, current outcomes of ISGPS-D PD remain unknown as large nationwide series are lacking.

METHODS:

Nationwide retrospective analysis including consecutive patients undergoing ISGPS-D PD (i.e., soft texture and pancreatic duct ≤3 mm), using the mandatory Dutch Pancreatic Cancer Audit (2014-2021). Primary outcome was in-hospital mortality and secondary outcomes included major morbidity (i.e., Clavien-Dindo grade ≥IIIa) and POPF (ISGPS grade B/C). The use of prophylactic TP to avoid POPF during the study period was assessed.

RESULTS:

Overall, 1402 patients were included. In-hospital mortality was 4.1% (n=57), which decreased to 3.7% (n=20/536) in the last 2 years. Major morbidity occurred in 642 patients (45.9%) and POPF in 410 (30.0%), which corresponded with failure to rescue in 8.9% (n=57/642). Patients with POPF had increased rates of major morbidity (88.0% vs. 28.3%; P<0.001) and mortality (6.3% vs. 3.5%; P=0.016), compared to patients without POPF. Among 190 patients undergoing TP, prophylactic TP to prevent POPF was performed in 4 (2.1%).

CONCLUSION:

This nationwide series found a 4.1% in-hospital mortality after ISGPS-D PD with 45.9% major morbidity, leaving little room for improvement through prophylactic TP. Nevertheless, given the outcomes in 30% of patients who develop POPF, future randomized trials should aim to prevent and mitigate POPF in this high-risk category.

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2023 Tipo del documento: Article